Method of treating alzheimer's disease with expanded natural killer cells
AssigneeNKMAX Co., Ltd.
InventorsPaul Y. Song, Sang Woo Park, Yong Man Kim
Life of this patent
Estimating the term…
Abstract
A method for treating Alzheimer's disease is disclosed. The method comprises identifying a subject and treating the subject with expanded natural killer cells (NKs). A composition for treating Alzheimer's disease is also disclosed.
Claims38
A method of treating Alzheimer's disease in a subject, the method comprising:
- a. identifying a subject, wherein the subject has Alzheimer's;
- and
- b. administering to the subject an expanded natural killer (NK) cell population, wherein the NK cells are expanded by a method comprising:
- i) isolating at least one of CD56+ cells and/or CD3−/CD56+ cells from the PBMCs;
- ii) co-culturing the at least one of CD56+ cells and/or CD3−/CD56+ cells with a combination of feeder cells in the presence of at least two cytokines;
- iii) wherein the combination of feeder cells comprises irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells;
- and
- iv) wherein the at least two cytokines comprise IL-2 and IL-21.
A method of cell therapy comprising:
- a. identifying a subject, wherein the subject has Alzheimer's disease;
- and
- b. administering to the subject an expanded NK cell population, wherein the NK cells are expanded by a method comprising:
- i) isolating at least one of CD56+ cells and/or CD3−/CD56+ cells from the PBMCs;
- ii) co-culturing the at least one of CD56+ cells and/or CD3−/CD56+ cells with a combination of feeder cells in the presence of at least two cytokines;
- iii) wherein the combination of feeder cells comprises irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells;
- and
- iv) wherein the at least two cytokines comprise IL-2 and IL-21.
A population of expanded NK cells, wherein the NK cells were expanded by a method that comprises:
- v) isolating at least one of CD56+ cells and/or CD3−/CD56+ cells from the PBMCs;
- vi) co-culturing the at least one of CD56+ cells and/or CD3−/CD56+ cells with a combination of feeder cells in the presence of at least two cytokines;
- vii) wherein the combination of feeder cells comprises irradiated Jurkat cells and irradiated Epstein-Barr virus transformed lymphocyte continuous line (EBV-LCL) cells;
- and
- viii) wherein the at least two cytokines comprise IL-2 and IL-21;
- and
- wherein the population of expanded NK cells has been administered to a subject who has Alzheimer's disease.
A method of treating Alzheimer's disease in a subject, the method comprising:
- a. identifying a subject, wherein the subject has Alzheimer's disease;
- and
- b. administering to the subject a therapeutically effective amount of a NK cell population (e.g., an autologous NK cell population).
The method of any one of the preceding claims, further comprising administration of one or more secondary Alzheimer's disease therapeutics.
A kit comprising the NK cell population of any one of the preceding claims and one or more secondary Alzheimer's disease therapeutics.
A formulation comprising the NK cell population of any one of the preceding claims and one or more secondary Alzheimer's disease therapeutics.
The method of any one of the preceding claims, wherein identifying a subject as having Alzheimer's disease comprises detecting and/or quantifying one or more biomarkers.
The method of any one of the preceding claims, wherein identifying a subject as having Alzheimer's disease comprises administering one or more cognitive assessments.
The method of any one of the preceding claims, wherein administration of the NK cells decreases neuroinflammation in the subject as compared to the level of neuroinflammation in the subject prior to administration of the NK cells.
The method of any one of the preceding claims, wherein the NK cells are administered intravenously.
The method of any one of the preceding claims, wherein the expanded NK cell population or the NK cell population is or comprises SNK01.
Dependencies are inferred from the claim text.